Zobrazeno 1 - 10
of 129
pro vyhledávání: '"Bella Ungar"'
Autor:
Stav Dan, Bella Ungar, Shani Ben-Moshe, Keren Bahar Halpern, Miri Yavzori, Ella Fudim, Orit Picard, Chaya Mushka Abitbol, Sivan Harnik, Iris Barshack, Uri Kopylov, Shomron Ben-Horin, Shalev Itzkovitz
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 16, Iss 1, Pp 1-15 (2023)
Background & Aims: Noninvasive modalities for assessing active endoscopic and histologic inflammation in Crohn’s disease and ulcerative colitis patients are critically needed. Fecal wash host shed-cell transcriptomics has been shown to be a robust
Externí odkaz:
https://doaj.org/article/6bf6f05d637e4258a95891889dccaca2
Publikováno v:
Case Reports in Gastroenterology, Vol 16, Iss 2, Pp 430-434 (2022)
Vedolizumab-associated adverse effects, including infusion reactions, are generally uncommon. Less than 5% of patients experience an infusion-related reaction. We report a 67-year-old male with ulcerative colitis under prolonged maintenance therapy w
Externí odkaz:
https://doaj.org/article/725fe4005df8409da684e611858f6920
Autor:
Asaf Levartovsky, Ido Cohen, Chaya Mushka Abitbol, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Shomron Ben-Horin, Bella Ungar
Publikováno v:
Biomedicines, Vol 11, Iss 6, p 1553 (2023)
Background: Vedolizumab trough serum levels have been associated with clinical and endoscopic response in patients with inflammatory bowel disease (IBD). A recent study demonstrated that higher trough levels before dose escalation are associated with
Externí odkaz:
https://doaj.org/article/63fcd4a1d5554ed4b7627e203200b6bc
Autor:
Zohar Ben-Shatach, Tomer Ziv-Baran, Ella Fudim, Miri Yavzori, Orit Picard, Asaf Levartovsky, Limor Selinger, Batia Weiss, Uri Kopylov, Rami Eliakim, Bella Ungar
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Higher infliximab trough levels (TLs) correlate with better clinical, inflammatory, and endoscopic outcomes among inflammatory bowel disease (IBD) patients. Although standard scheduled infliximab therapy regimen consists of infusions at p
Externí odkaz:
https://doaj.org/article/5485291456cf4c45a2307114ad38611c
Autor:
Henit Yanai, Bella Ungar, Uri Kopylov, Tali Sharar Fischler, Irit Avni Biron, Jacob E. Ollech, Idan Goren, Manar Matar, Tsachi Tsadok Perets, Raanan Shamir, Iris Dotan, Shira Amir, Amit Assa
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Evidence regarding the risk of immunogenicity in patients with inflammatory bowel disease (IBD) who switched anti-tumor necrosis factor alpha (anti-TNFα) therapies to a subsequent anti-TNFα (either infliximab or adalimumab) is conflicti
Externí odkaz:
https://doaj.org/article/30e35f9753834cd797022ad1503b10ec
Autor:
Asaf Levartovsky, Yiftach Barash, Shomron Ben-Horin, Bella Ungar, Shelly Soffer, Marianne M. Amitai, Eyal Klang, Uri Kopylov
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Intra-abdominal abscess (IA) is an important clinical complication of Crohn’s disease (CD). A high index of clinical suspicion is needed as imaging is not routinely used during hospital admission. This study aimed to identify clinical p
Externí odkaz:
https://doaj.org/article/b840592fef9244ffa0f2f9aed4759879
Autor:
Offir Ukashi, Yifatch Barash, Michael J. Segel, Bella Ungar, Shelly Soffer, Shomron Ben-Horin, Eyal Klang, Uri Kopylov
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 13 (2020)
Background: Community-acquired pneumonia is among the most common infections affecting ulcerative colitis and Crohn’s disease patients. Data regarding epidemiology and outcomes of pneumonia in inflammatory bowel disease patients is lacking. We aime
Externí odkaz:
https://doaj.org/article/74439037334b4a619b4aa85e030507ea
Autor:
Lev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya’acov, Irit Avni-Biron, Baruch Ovadia, Ofer Ben-Bassat, Timna Naftali, Uri Kopylov, Yael Haberman, Hagar Banai Eran, Rami Eliakim, Adi Lahat-Zok, Ayal Hirsch, Eran Zittan, Nitsan Maharshak, Matti Waterman, Eran Israeli, Idan Goren, Jacob E. Ollech, Henit Yanai, Bella Ungar, Benjamin Avidan, Dana Ben Hur, Bernardo Melamud, Ori Segol, Zippora Shalem, Iris Dotan, Selwyn H. Odes, Shomron Ben-Horin, Yf’at Snir, Yael Milgrom, Efrat Broide, Eran Goldin, Shmuel Delgado, Yulia Ron, Nathaniel Aviv Cohen, Eran Maoz, Maya Zborovsky, Safwat Odeh, Naim Abu Freha, Eyal Shachar, Yehuda Chowers, Tal Engel, Hila Reiss-Mintz, Arie Segal, Adar Zinger, Ariella Bar-Gil Shitrit
Publikováno v:
Vaccines, Vol 10, Iss 3, p 376 (2022)
Background: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated inflammatory bowel diseases (IBD) affecting millions of people worldwide. IBD therapies, designed for continuous immune suppression, often render patients mor
Externí odkaz:
https://doaj.org/article/eca69cf35e7040a98fb236c6175f11ed
Autor:
Anna Vaisman-Mentesh, Shai Rosenstein, Miri Yavzori, Yael Dror, Ella Fudim, Bella Ungar, Uri Kopylov, Orit Picard, Aya Kigel, Shomron Ben-Horin, Itai Benhar, Yariv Wine
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Drugs formulated from monoclonal antibodies (mAbs) are clinically effective in various diseases. Repeated administration of mAbs, however, elicits an immune response in the form of anti-drug-antibodies (ADA), thereby reducing the drug's efficacy. Not
Externí odkaz:
https://doaj.org/article/dc1b529342da4cb7b6f48cbaa0cfd210
Autor:
Moran Livne-Margolin, Daniel Ling, Shani Attia-Konyo, Chaya Mushka Abitbol, Ola Haj-Natour, Bella Ungar, Shomron Ben-Horin, Uri Kopylov
Publikováno v:
Digestive and Liver Disease. 55:223-229
Extraintestinal manifestations (EIM) are associated with diminished quality of life. The efficacy of Ustekinumab and vedolizumab for EIM treatment is not well established. The aim was to compare the effectiveness of ustekinumab and vedolizumab for tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2c8dba3064601684e0a27bdaec4173c
https://doi.org/10.1016/j.dld.2022.09.009
https://doi.org/10.1016/j.dld.2022.09.009